Leading hospital chain Apollo Hospitals Enterprises Ltd (Ahel) has posted a consolidated net profit of Rs 477 crore during the second quarter this financial year, up 26 per cent from Rs 379 crore during the same period last financial year.
Apollo Hospitals Enterprise Ltd (AHEL) on Tuesday said its ongoing restructuring aims to unlock the value of its omni-channel pharmacy and digital businesses, while enhancing shareholder returns. The newly-formed entity is expected to achieve a year-on-year growth rate of 22-23 per cent, driven by the e-pharmacy segment and other business verticals, with a revenue target of Rs 25,000 crore by the financial year 2027.
Revenues from Bangladeshi patients have declined by 30% to 35% in 2024-2025. Bangladesh typically accounts for 70% to 75% of all medical visas issued by India.
The stock of Apollo Hospitals Enterprise (AHEL), India's largest listed health care services company, fell 4.6 per cent on Monday (April 29) and slipped another 0.34 per cent to close at Rs 5,946.20 on Tuesday (April 30). The share declined due to a lower valuation for subsidiary Apollo HealthCo (AHL) and an aggressive valuation for Keimed, a promoter-owned drug wholesaler that is merging with AHL.
According to a recent CareEdge Ratings report, Bangladesh accounts for around 50-60 per cent of India's total medical tourism inflow
Apollo HealthCo Ltd (AHL), a subsidiary of Apollo Hospitals Enterprise (AHEL), on Friday entered into a binding agreement to raise equity capital of Rs 2,475 crore from Advent International (Advent), one of the world's largest private equity (PE) players. The transaction will also see the merger of two units under Apollo Healthco - its wholesale pharma distribution unit Keimed Pvt Ltd and online healthcare business Apollo 24'7. The merger will take place in a phased manner over the next 24-30 months.
AHEL had earlier said it was looking for a strategic partner with international experience for its pharma business.
The group wants to expand its drug store chain.